Diagnostic tests and prognostic indicators

Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma. Watanabe T et al. PLoS One. 2015 Jun 26;10(6):e0128662. doi: 10.1371/journal.pone.0128662. High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma. Chhabra S et al. J…

Related conditions

Vasotropic light-chain amyloidosis and ischaemic cholangiopathy. Johnston EL et al. BMJ Case Rep. 2015 Jun 25;2015. pii: bcr2015210883. doi: 10.1136/bcr-2015-210883. Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. Cao X et al. J Hematol Oncol. 2015 Jun 24;8(1):74. [Epub ahead of print]. Hepatocyte growth factor measurement in AL amyloidosis. Abraham J et al Amyloid. 2015 Jun 8:1-5. [Epub ahead of…

Emerging treatments

Safety of a second-generation tyrosine kinase inhibitor and novel targeted therapy for the treatment of a patient with chronic myeloid leukemia and multiple myeloma. Katzel JA et al. Anticancer Drugs. 2015 Jun 23. [Epub ahead of print]. Haematalogical cancer: Elotuzumab reduces risk of multiple myeloma progression. [No authors listed]. Nat Rev Clin Oncol. 2015 Jun 23. doi: 10.1038/nrclinonc.2015.115. [Epub ahead of print]. Lenalidomide…

Biology and genetics

Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma. Zang M et al. Cancer Lett. 2015 Jun 23. pii: S0304-3835(15)00403-6. doi: 10.1016/j.canlet.2015.06.011. [Epub ahead of print]. Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Kandela I et al. Elife. 2015 Jun 25;4. doi: 10.7554/eLife.07072. KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. Riz I et…

Supportive care

Safety and efficacy of kyphoplasty in the treatment of tumoral disease of the spine. García-Maroto R et al. Rev Esp Cir Ortop Traumatol. 2015 Jun 19. pii: S1888-4415(15)00058-2. doi: 10.1016/j.recot.2015.05.003. [Epub ahead of print]. Risks and Benefits of Bisphosphonate Therapies. Reyes C er al. J Cell Biochem. 2015 Jun 20. doi: 10.1002/jcb.25266. [Epub ahead of print]. Adherence to analgesics for cancer…

General

Differentiated plasma cell myeloma presenting as a solitary spinal amyloidoma: A case report, possible pitfall and review to the literature. Brawanski N et al. Clin Neurol Neurosurg. 2015 Jun 10;137:1-4. doi: 10.1016/j.clineuro.2015.05.027. [Epub ahead of print]. Regulatory Perspective on Minimal Residual Disease Flow Cytometry Testing in Multiple Myeloma. Gormley NJ et al. Cytometry B Clin Cytom. 2015 Jun 23. doi: 10.1002/cyto.b.21268. [Epub ahead of…

Complications of myeloma and its treatments

Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Teh BW et al. Br J Haematol. 2015 Jun 24. doi: 10.1111/bjh.13532. [Epub ahead of print]. Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications. Undas A et al. Blood Coagul Fibrinolysis. 2015 Jun 11. [Epub…

Current treatments

The Feasibility and Efficacy of Dose-Adjusted Bortezomib, Melphalan and Dexamethasone for Transplantation-Ineligible Patients with Newly Diagnosed Multiple Myeloma. Obama K. Acta Haematol. 2015 Jun 11;134(4):229-230. [Epub ahead of print]/ Biosimilar filgrastim (Zarzio®) vs Lenograstim (Myelostim®) for peripheral blood stem cell mobilization in adult patients with myeloma and lymphoma: A single center experience. Marchesi F et al. Leuk Lymphoma. 2015 Jun 23:1-12.…

Diagnostic tests and prognostic indicators

Inter-observer agreement for the evaluation of bone involvement on Whole Body Low Dose Computed Tomography (WBLDCT) in Multiple Myeloma (MM). Zacchino M et al. Eur Radiol. 2015 May 20. [Epub ahead of print]. Global hypomethylation in myeloma is associated with poor prognosis. Sive JI et al. Br J Haematol. 2015 May 26. doi: 10.1111/bjh.13506. [Epub ahead of print]. Circulating plasma cells in newly diagnosed symptomatic multiple…

Related conditions

A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. Cibeira MT et al. Br J Haematol. 2015 May 14. doi: 10.1111/bjh.13500. [Epub ahead of print]. Bortezomib in type I cryoglobulinemic vasculitis: are we acting too late? Ramirez GA et al. Intern Med. 2015;54(9):1119-23. doi: 10.2169/internalmedicine.54.3668. Epub 2015 May 1. Abnormal FISH…